艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ADC 艾格里房产

盘后交易 05-29 18:54:15 EDT

74.15

-0.13

-0.18%

盘后74.00

-0.15-0.20%

18:28 EDT

最高74.37	最低73.46	成交量179.85万
今开74.11	昨收74.28	日振幅1.23%
总市值89.00亿	流通市值80.35亿	总股本1.20亿
成交额1.33亿	换手率1.66%	流通股本1.08亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ADC","market":"US","secType":"STK","nameCN":"艾格里房产","latestPrice":74.15,"timestamp":1780084800000,"preClose":74.283,"halted":0,"volume":1798470,"hourTrading":{"tag":"盘后","latestPrice":74,"preClose":74.15,"latestTime":"18:28 EDT","volume":116147,"amount":8612239.072825,"timestamp":1780093700101,"change":-0.15,"changeRate":-0.002023,"amplitude":0.002055},"delay":0,"changeRate":-0.0017904500356743208,"floatShares":108366822,"shares":120028300,"eps":1.85165,"marketStatus":"盘后交易","change":-0.133,"latestTime":"05-29 18:54:15 EDT","open":74.11,"high":74.37,"low":73.46,"amount":133150014.2052,"amplitude":0.01225,"askPrice":74.1,"askSize":30,"bidPrice":73.77,"bidSize":500,"shortable":3,"etf":0,"ttmEps":1.85165,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1780099200000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":766296000000,"exchange":"NYSE","adjPreClose":74.283,"dividendRate":0.04191,"preHourTrading":{"tag":"盘前","latestPrice":74.35,"preClose":74.283,"latestTime":"09:08 EDT","volume":7,"amount":519.6300200000001,"timestamp":1780060130685,"change":0.067,"changeRate":0.000902,"amplitude":0.008481},"postHourTrading":{"tag":"盘后","latestPrice":74,"preClose":74.15,"latestTime":"18:28 EDT","volume":116147,"amount":8612239.072825,"timestamp":1780093700101,"change":-0.15,"changeRate":-0.002023,"amplitude":0.002055},"volumeRatio":1.636995,"impliedVol":0.2424,"impliedVolPercentile":0.8048},"requestUrl":"/m/hq/s/ADC","defaultTab":"news","newsList":[{"id":"2639648279","title":"港股异动 | 德琪医药-B(06996)涨超5% ATG-022 ADC治疗相关胃腺癌关键性III期CLINCH-3研究获临床批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2639648279","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639648279?lang=zh_cn&edition=full","pubTime":"2026-05-29 09:53","pubTimestamp":1780019635,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，德琪医药-B涨超5%，截至发稿，涨5.33%，报4.35港元，成交额327.19万港元。消息面上，德琪医药-B发布公告，经中国国家药品监督管理局(药监局)药品审评中心审评，本公司已获药审中心核准同意开展关于ATG-022用于治疗CLDN18.2+晚期胃或胃食管结合部腺癌的关键性III期CLINCH-3研究。本集团无法保证ATG-022最终将成功开发及上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447541.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06996","BK1191","BK4231","BK4585","BK4588","BK1574","BK4080","BK1583","ADC","III","BK4134","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638687536","title":"艾伯维(ABBV.US)CD123 ADC获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2638687536","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638687536?lang=zh_cn&edition=full","pubTime":"2026-05-28 15:36","pubTimestamp":1779953784,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，艾伯维宣布美国FDA已经批准其ADC疗法Pivekimab sunirine上市，用于治疗母细胞性浆细胞样树突细胞肿瘤。资料显示，这是全球首个获批上市的CD123 ADC，也是艾伯维首个获批的血液瘤ADC。Pivekimab sunirine是一款靶向CD123的ADC，拟开发用于治疗血液系统恶性肿瘤。CD123靶点在BPDCN肿瘤细胞中呈高度特异性高表达，是该病理想的治疗靶点。美国FDA已于2020年10月授予该药物BPDCN适应症突破性疗法认定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447086.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0820561909.HKD","IE00BLSP4239.USD","LU0795875169.SGD","LU0965509101.SGD","LU2089284900.SGD","IE00BBT3K403.USD","LU2357627491.SGD","SG9999015986.USD","ABBV","BK4581","LU2237443465.HKD","IE00BVYPNV92.GBP","LU0211327993.USD","LU1267930490.SGD","LU1732799900.SGD","LU0158827948.USD","LU1037948897.HKD","SG9999015978.USD","BK4566","LU2237443895.HKD","BK4559","LU0289739343.SGD","LU0289961442.SGD","BK4080","IE00B42XCP33.USD","IE000BZT7R73.USD","LU0198837287.USD","LU0965509283.SGD","LU1023059063.AUD","LU1061106388.HKD","LU1267930573.SGD","LU1839511570.USD","LU0029864427.USD","IE0002270589.USD","LU0114720955.EUR","LU0661504455.SGD","SG9999003800.SGD","LU1244550494.USD","SG9999011175.SGD","LU0472753341.HKD","LU0965509010.AUD","BK4533","ADC","LU1718418525.SGD","LU2133065610.SGD","LU1989771016.USD","LU1934455277.USD","IPOS","IE0000B7K699.USD","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638457426","title":"港股异动 | 映恩生物-B(09606)涨超5% 与BioNTech合作开发B7-H3 ADC全球Ⅲ期临床完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2638457426","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638457426?lang=zh_cn&edition=full","pubTime":"2026-05-27 14:56","pubTimestamp":1779864979,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，映恩生物-B涨超5%，截至发稿，涨3.14%，报222.6港元，成交额1.52亿港元。消息面上，近日，据映恩生物-B官微消息，公司宣布，与BioNTech SE合作开发的靶向B7-H3的抗体偶联药物DB-1311/BNT324用于治疗未接受过紫杉烷类化疗的转移性去势抵抗性前列腺癌患者的全球Ⅲ期关键性注册临床研究已顺利完成全球首例患者入组给药。2026年5月12日，映恩生物行使独家选择权，参与分摊DB-1311/BNT324在美国地区的研发成本，并共享该药物商业化运营产生的盈亏收益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446515.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4080","BK1161","ADC","BK4588","HK0000252152.HKD","HK0000252160.HKD","BK4231","LU2543165471.USD","VXUS","HK0000500386.USD","09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636356678","title":"重磅ADC药物获批多发性骨髓瘤二线联合用药，GSK中国特药业务部负责人：肿瘤是未来GSK重要增长引擎之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2636356678","media":"蓝鲸财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636356678?lang=zh_cn&edition=full","pubTime":"2026-05-19 15:41","pubTimestamp":1779176518,"startTime":"0","endTime":"0","summary":"值得注意的是，倍乐锐是GSK肿瘤领域的重磅药物。据GSK全球一季度财报，该药物在今年一季度收入达2300万英镑，在该款药物的加持下，肿瘤业务也已经是GSK当前业绩增长最快的板块。今年第一季度，GSK肿瘤业务销售额同比增长28%，达到5.12亿英镑，业务增速在所有业务中位居第一。GSK副总裁、中国特药业务部负责人张宁向蓝鲸新闻表示，GSK未来会考虑布局更多的ADC药物、小分子药物等形成合力，包括肿瘤在内的特药业务是未来GSK很重要的增长引擎之一。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1779176429659930072","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["ADC","LU1829250122.USD","GSKH","BK4080","GSK","BK4588","GSK.UK","BK4231","BK4532","BK4585","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635085638","title":"百亿ADC抗癌药赛道迎新玩家，药企期待多元化支付提高可及性","url":"https://stock-news.laohu8.com/highlight/detail?id=2635085638","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635085638?lang=zh_cn&edition=full","pubTime":"2026-05-15 18:17","pubTimestamp":1778840220,"startTime":"0","endTime":"0","summary":"国内ADC（抗体偶联）领域又迎来重磅选手！近日，葛兰素史克（GSK）宣布，其注射用玛贝兰妥单抗（商品名：倍乐锐）与硼替佐米和地塞米松（BVd）联合用于治疗既往接受过至少一线治疗的多发性骨髓瘤成年患者。该药是目前唯一一个获批用于治疗多发性骨髓瘤的抗B细胞成熟抗原（BCMA）ADC药物，可在多种治疗场景中以30分钟的门诊输注方式满足患者多样化的治疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605153739072253.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605153739072253.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ADC","BK4080","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634629466","title":"百利天恒：iza-bren（EGFR×HER3双抗ADC）获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2634629466","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634629466?lang=zh_cn&edition=full","pubTime":"2026-05-12 17:18","pubTimestamp":1778577480,"startTime":"0","endTime":"0","summary":"南财智讯5月12日电，百利天恒公告，iza-bren（EGFR×HER3双抗ADC）收到国家药品监督管理局《药物临床试验批准通知书》（通知书编号：2026LP01442），同意该药开展联合小分子靶向药物用于治疗驱动基因阳性的局部晚期或转移性非小细胞肺癌的临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605123734555430.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02615","BK4080","91194","ADC","688506","BK4231","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633432300","title":"科伦博泰生物(06990)：核心产品TROP2 ADC芦康沙妥珠单抗(sac-TMT) 新增适应症上市申请获国家药品监督管理局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2633432300","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633432300?lang=zh_cn&edition=full","pubTime":"2026-05-08 18:16","pubTimestamp":1778235396,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物 发布公告，近日，本公司靶向人滋养细胞表面抗原2 的抗体偶联药物芦康沙妥珠单抗 (佳泰莱)的一项新增适应症上市申请(该申请)已获中国国家药品监督管理局药品审评中心受理。本次受理是基于OptiTROP-Lung05注册3 期研究的积极结果，该申请是芦康沙妥珠单抗获NMPA受理的第五项适应症上市申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439642.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4080","BK1161","LU0196878994.USD","06990","ADC","BK4231","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629001368","title":"从AACR看中国创新：ADC与双抗领跑 授权交易见证含金量","url":"https://stock-news.laohu8.com/highlight/detail?id=2629001368","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629001368?lang=zh_cn&edition=full","pubTime":"2026-04-23 13:00","pubTimestamp":1776920400,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者季媛媛1907年的华盛顿，11位医生与科学家随手组建的“小圈子”，谁也没想到会演变成今天全球癌症研究领域最负盛名的盛会——美国癌症研究协会（AACR）。一百多年后的今天，AACR年会早已不只是一场学术会议，更是全球肿瘤研发的“晴雨表”和“风向标”。对中国生物医药产业而言，AACR也成为观察创新活力与国际化进程的最佳窗口。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604233715799065.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604233715799065.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4231","BK4080","ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629079406","title":"创胜集团医药-B(06628)公布其新型LIV1 ADC TST013在前列腺癌及 ER阳性╱HER2阴性乳腺癌PDX模型中显示出强大的抗肿瘤活性的新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2629079406","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629079406?lang=zh_cn&edition=full","pubTime":"2026-04-23 07:00","pubTimestamp":1776898849,"startTime":"0","endTime":"0","summary":"智通财经APP讯，创胜集团医药-B 公布，于2026年AACR年会上发表强调其自主研发的LIV1抗体偶联药物的临床前数据。对于LIV1表达的前列腺癌PDX模型，ADC-2在给药两剂后显示出有限的肿瘤生长抑制。总体而言，该等数据证明创胜医药的LIV1 ADC-2及ADC-3项目在ER阳性╱Her2 阴性乳腺癌以及前列腺癌的PDX模型中作为单药疗法显示出强大的抗肿瘤活性。该等结果支持进一步研究创胜医药的LIV1 ADC在LIV1阳性实体瘤中的应用。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432372.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK4080","BK1161","PDX","159938","09939","BK1574","ADC","06628","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629961098","title":"新一代TROP 2 ADC达卓优在华上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2629961098","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629961098?lang=zh_cn&edition=full","pubTime":"2026-04-22 10:13","pubTimestamp":1776823980,"startTime":"0","endTime":"0","summary":"南方财经4月22日电，阿斯利康与第一三共合作开发并引入中国的第二款ADC药物达卓优?（英文商品名:Datroway?，通用名：注射用德达博妥单抗）在中国正式上市，首批到货将陆续在全国各地医院和药房落地启用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604223713715630.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4080","IPOS","BK4231","ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629906669","title":"中国生物制药(01177)：礼新医药于AACR 2026公布两款ADC最新研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2629906669","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629906669?lang=zh_cn&edition=full","pubTime":"2026-04-22 06:16","pubTimestamp":1776809789,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 公布，该集团全资附属公司礼新医药科技(上海)有限公司自主研发的两款新一代抗体偶联药物 LM-364 “Nectin-4TME ADC”及LM-338 “STn ADC”，于2026年美国癌症研究协会年会公布最新研究数据。LM-364是礼新医药依托自主开发的肿瘤微环境平台开发的新一代Nectin-4TME ADC。目前，LM-364已向美国食品药品监督管理局递交新药临床试验申请，计划于2026年启动首次人体临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431634.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4080","09939","159938","ADC","BK1574","BK1161","BK1589","BK1191","IE00BZ08YS42.EUR","BK1515","IE00BZ08YT58.USD","BK1521","BK4231","HK0000165453.HKD","IE00BZ08YR35.GBP","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628790385","title":"卡位ADC、TCE前沿赛道，迈威生物(02493)港股IPO含金量有几分？","url":"https://stock-news.laohu8.com/highlight/detail?id=2628790385","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628790385?lang=zh_cn&edition=full","pubTime":"2026-04-20 09:40","pubTimestamp":1776649207,"startTime":"0","endTime":"0","summary":"2026年4月20日，迈威生物正式启动招股程序，中信证券与海通国际担任联席保荐人。在这一波创新药出海浪潮中，手握全球领先管线的迈威生物无疑将受到市场密切关注。通过ADC与TCE双平台驱动，叠加多元化的创新管线布局，迈威生物正在肿瘤治疗领域构建起差异化的强大竞争壁垒。从业绩来看，迈威生物已交出了一份颇具说服力的答卷：2024-","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430463.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688062","IPOS","BK4080","VXUS","BK4588","BK4585","02493","BK0239","ADC","BK4231","SPCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628292792","title":"迈威生物（2493.HK）：Nectin-4 ADC领跑，ST2单抗蓄势，多领域布局下的价值图谱","url":"https://stock-news.laohu8.com/highlight/detail?id=2628292792","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628292792?lang=zh_cn&edition=full","pubTime":"2026-04-20 09:03","pubTimestamp":1776646985,"startTime":"0","endTime":"0","summary":"当A+H双平台为它打开新的资本窗口，当生物医药成为国家支柱产业的大势已经明朗，迈威生物已从一家biotech成长为能自己造血、自己生产、自己卖药的全产业链biopharma，未来值得期待。","market":"hk","thumbnail":"https://img2.gelonghui.com/d273d-800407fd-2249-448f-b352-5198e098082d.jpg?guru_height=855&guru_width=1280&guru_size=118253","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/d273d-800407fd-2249-448f-b352-5198e098082d.jpg?guru_height=855&guru_width=1280&guru_size=118253"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4463975","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["ADC","BK4231","BK4080","BK0239","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628794281","title":"基石药业-B(02616)携CS5007(EGFR/HER3)等三款全新/差异化ADC临床前研究成果亮相AACR年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2628794281","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628794281?lang=zh_cn&edition=full","pubTime":"2026-04-20 08:04","pubTimestamp":1776643475,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 公布，公司在2026年4月17日至22日召开的美国癌症研究协会年会上展出包括CS5007、CS5006及CS5008在内三项自主研发管线的临床前最新研究成果。CS5007是一种双特异性ADC,由抗EGFR/HER3人源IgG1抗体、基石药业专有的亲水性CSL20连接子，以及临床验证的拓扑异构酶I抑制剂Exatecan组成。此外，CS5008抗体产量高、ADC稳定性强、成药性良好。基石药业计划于2026年下半年正式启动CS5008的IND申请工作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430419.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02616","BK4080","BK1574","BK4231","ADC","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627407539","title":"中国生物制药(01177)：维特柯妥拜单抗“CLDN18.2 ADC”一线胃及胃食管交界部腺癌III期临床试验完成首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2627407539","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627407539?lang=zh_cn&edition=full","pubTime":"2026-04-15 17:02","pubTimestamp":1776243779,"startTime":"0","endTime":"0","summary":"本研究为LM-302开展的第二项Ⅲ期临床试验，也是全球首个CLDN18.2 ADC药物采用无化疗方案用于胃癌一线治疗的Ⅲ期临床试验。这种“ADC+免疫”联合策略有望为CLDN18.2阳性胃癌患者带来更深度的肿瘤缓解。除本次启动的LM-302联合疗法用于一线治疗CLDN18.2阳性GC/GEJ的III期临床外，LM-302单药用于三线及以上CLDN18.2阳性GC/GEJ的III期临床研究已完成全部受试者入组。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428818.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","BK4080","BK4134","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","BK1589","01177","BK4231","III","BK1515","ADC","BK1521","IE00BZ08YS42.EUR","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627478451","title":"加速全球ADC龙头价值构建，映恩生物-B(09606)推动“H+A”双资本平台布局释放长投信号","url":"https://stock-news.laohu8.com/highlight/detail?id=2627478451","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627478451?lang=zh_cn&edition=full","pubTime":"2026-04-15 08:00","pubTimestamp":1776211200,"startTime":"0","endTime":"0","summary":"4月13日晚，ADC龙头企业映恩生物-B发布公告宣布：董事会批准了发行人民币股份并在科创板上市的计划。对于映恩生物而言，自2025年6月成功实现港股上市后，此次拟申报科创板上市意味着公司正积极锚向“H+A”双资本平台布局，以进一步拓宽企业融资渠道、支持在研管线的临床推进及技术平台建设。作为全球ADC药物创新研发的前沿领导者之一，映恩生物的技术价值也获得了国际业界的高度认可。目前，双方联合用药的临床进展全球领先。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428586.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4231","BK4080","HK0000252152.HKD","ADC","HK0000252160.HKD","HK0000500386.USD","09606","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627494406","title":"“明星”抗癌药中国“七连发”：跨国药企加速重塑在华商业模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2627494406","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627494406?lang=zh_cn&edition=full","pubTime":"2026-04-14 13:17","pubTimestamp":1776143820,"startTime":"0","endTime":"0","summary":"近日，由阿斯利康与第一三共共同开发与商业化的德曲妥珠单抗在中国取得新突破：其序贯THP疗法用于HER2阳性早期乳腺癌新辅助治疗的适应症实现“全球首批”，中国患者成为全球最早受益于这一创新疗法的群体。这并非德曲妥珠单抗在中国的首次亮相。自2023年首次获批以来，这款被称为“大魔王”的抗体偶联药物（ADC）在中国接连拿下七项适应症，覆盖乳腺癌、肺癌、胃癌等多个领域。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604143704221860.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604143704221860.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ADC","BK1574","BK4231","BK4080","06978","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143072653","title":"财报前瞻｜艾格里房产本季度营收预计增17.32%，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1143072653","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143072653?lang=zh_cn&edition=full","pubTime":"2026-04-14 08:52","pubTimestamp":1776127951,"startTime":"0","endTime":"0","summary":"艾格里房产将于2026年04月21日发布最新季度财报，市场关注营收与调整后每股收益的同比增长以及分红持续性。当前公开预期未提供本季度毛利率与净利润或净利率的具体数值。艾格里房产上一季度营收1.90亿美元，同比增长18.51%；毛利率87.40%；归属于母公司股东的净利润为5,603.70万美元，环比增长7.52%；净利率29.42%；调整后每股收益0.47美元，同比增长14.63%。本季度营收一致预期为1.92亿美元、同比增长17.32%，显示租金规模与资产投放节奏仍处在上行区间。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜艾格里房产本季度营收预计增17.32%，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159214626","title":"艾格里房产宣布上调月度现金股息至每股0.267美元，环比增长1.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1159214626","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159214626?lang=zh_cn&edition=full","pubTime":"2026-04-10 04:06","pubTimestamp":1775765173,"startTime":"0","endTime":"0","summary":"艾格里房产（Agree Realty Corp）最新宣布，将普通股月度现金股息提升至每股0.267美元，较上月增长1.9%。此次调升体现了公司稳健的现金流状况与持续回报股东的承诺。作为以净租赁零售物业为核心业务的房地产投资信托基金，艾格里房产通过定期股息调整，进一步强化其长期价值主张。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","ADC","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625303955","title":"50亿美元掷向ADC赛道，吉利德科学(GILD.US)高价收购德国Tubulis","url":"https://stock-news.laohu8.com/highlight/detail?id=2625303955","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625303955?lang=zh_cn&edition=full","pubTime":"2026-04-07 21:15","pubTimestamp":1775567710,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，吉利德科学同意收购德国私营生物技术公司 Tubulis GmbH，交易总价值高达 50 亿美元。吉利德目前已经销售一种名为 Trodelvy 的乳腺癌 ADC 药物。Tubulis 正在针对卵巢癌、肺癌以及其他类型的肿瘤进行药物临床试验。数据显示，卵巢癌市场到 2030 年的价值可能达到 56 亿美元，Tubulis 在该领域有潜力挑战阿斯利和礼来等巨头。这是吉利德今年以来的第三笔重大交易。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425591.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1934455194.USD","LU1037948541.HKD","LU1066053197.SGD","BK4139","LU0823416689.USD","LU0965509101.SGD","LU1674673691.USD","LU1934455277.USD","LU0114720955.EUR","LU0122379950.USD","GILD","LU0289739699.SGD","LU1061106388.HKD","LU0889565916.HKD","LU2089984988.USD","FDXMmain","BK4532","BK4566","LU2324357040.USD","SG9999015986.USD","LU2112291526.USD","BK4583","LU0965508806.USD","LU1839511570.USD","BK4231","LU0882574055.USD","IE0002270589.USD","LU0861579265.USD","LU0234570918.USD","SG9999015978.USD","IE00B19Z3B42.SGD","ADC","IE00BZ1G4Q59.USD","BK4080","IE00BSNM7G36.USD","FDAXmain","IE00BKVL7J92.USD","LU2468319806.SGD","BK4568","IE00B3T34201.USD","BK4578","LU1023059063.AUD","BK4588","LU0965509010.AUD","BK4550","LU1057294990.SGD","FDXSmain","LU0320765992.SGD","LU1585245621.USD","LU0965509283.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.agreerealty.com","stockEarnings":[{"period":"1week","weight":-0.0149},{"period":"1month","weight":-0.0299},{"period":"3month","weight":-0.0737},{"period":"6month","weight":-0.0089},{"period":"1year","weight":-0.0101},{"period":"ytd","weight":0.035}],"compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.0603},{"period":"3month","weight":0.1},{"period":"6month","weight":0.1042},{"period":"1year","weight":0.2839},{"period":"ytd","weight":0.1066}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Agree Realty Corporation成立于1971年，是马里兰州的一家公司。该公司是一家完全整合的房地产投资信托基金，主要专注于净出租给行业领先租户的零售物业的所有权、收购、开发和管理。","yearOnYearQuotes":[{"month":1,"riseRate":0.59375,"avgChangeRate":-0.003579},{"month":2,"riseRate":0.46875,"avgChangeRate":0.002186},{"month":3,"riseRate":0.5625,"avgChangeRate":0.012831},{"month":4,"riseRate":0.59375,"avgChangeRate":0.003425},{"month":5,"riseRate":0.484848,"avgChangeRate":0.014154},{"month":6,"riseRate":0.65625,"avgChangeRate":0.010123},{"month":7,"riseRate":0.65625,"avgChangeRate":0.022845},{"month":8,"riseRate":0.46875,"avgChangeRate":0.002201},{"month":9,"riseRate":0.46875,"avgChangeRate":-0.006321},{"month":10,"riseRate":0.5625,"avgChangeRate":-0.000339},{"month":11,"riseRate":0.65625,"avgChangeRate":0.003584},{"month":12,"riseRate":0.46875,"avgChangeRate":0.00994}],"exchange":"NYSE","name":"艾格里房产","nameEN":"Agree"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾格里房产(ADC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾格里房产,ADC,艾格里房产股票,艾格里房产股票老虎,艾格里房产股票老虎国际,艾格里房产行情,艾格里房产股票行情,艾格里房产股价,艾格里房产股市,艾格里房产股票价格,艾格里房产股票交易,艾格里房产股票购买,艾格里房产股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾格里房产(ADC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}